Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

No longer available 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Acute 9Leukemia 9Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 5Primary Immunodeficiency Diseases 3Multiple Myeloma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hodgkin Disease 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoproliferative Disorders 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7fludarabine 6Busulfan 5Tacrolimus 4Mycophenolic Acid 4ponatinib 2ibrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bone Marrow Transplantation 2Bendamustine Hydrochloride 2AP 1903 reagent 2thymoglobulin 1tetulomab tetraxetan lu-177 1durvalumab 1Rituximab 1Pharmacogenomic Testing 1Lymphocyte Depletion 1Lutetium-177 1Lutetium 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1CA-4948 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immune System Diseases × AP 1903 reagent × Other hematologic neoplasm × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03594162 2021-12-03

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer Center

No longer available
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡